2022
Evidence of accelerated epigenetic aging of breast tissues in patients with breast cancer is driven by CpGs associated with polycomb-related genes
Rozenblit M, Hofstatter E, Liu Z, O’Meara T, Storniolo AM, Dalela D, Singh V, Pusztai L, Levine M. Evidence of accelerated epigenetic aging of breast tissues in patients with breast cancer is driven by CpGs associated with polycomb-related genes. Clinical Epigenetics 2022, 14: 30. PMID: 35209953, PMCID: PMC8876160, DOI: 10.1186/s13148-022-01249-z.Peer-Reviewed Original ResearchConceptsNormal breast tissueBreast cancerEpigenetic age accelerationBreast tissuePeripheral bloodAge accelerationStrong risk factorBreast cancer riskTissue/blood samplesGood surrogate markerBreast cancer diagnosisHealthy controlsRisk factorsSurrogate markerCancer riskBlood samplesTumor tissueCancerCancer diagnosisNew scoreTissueUnaffected individualsBloodEpigenetic aging signaturesEpigenetic aging
2009
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D, Engels K, Karn T, Kaufmann M. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Research 2009, 11: r15. PMID: 19272155, PMCID: PMC2688939, DOI: 10.1186/bcr2234.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBreast NeoplasmsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansImmunoenzyme TechniquesLymphocyte Specific Protein Tyrosine Kinase p56(lck)Neoplasm StagingOligonucleotide Array Sequence AnalysisPrognosisReceptor, ErbB-2Receptors, EstrogenT-LymphocytesConceptsER-negative tumorsImmune cellsBreast cancer samplesSurrogate markerPrognostic valueBreast cancerHuman epidermal growth factor receptor 2 (HER2) amplificationHER2-positive breast cancerDifferent immune cell typesCancer samplesPrimary breast cancer samplesER-negative groupER-positive tumorsDifferent immune cellsSignificant prognostic valuePositive prognostic valueImmune cell typesSubgroup of tumorsPrognostic gene signatureNeoadjuvant chemotherapyFavorable prognosisCytokine milieuClinical parametersNegative tumorsWorse prognosis